Beta Bionics reports Q3 sales up 30% and raises 2026 revenue outlook after FDA clearance for Mint
Beta Bionics posted third‑quarter 2026 net sales of $35.5 million, a 30% year‑over‑year increase, while its net loss widened to $24.4 million. The company raised its full‑year 2026 revenue guidance to $124 million‑$126 million and disclosed a public offering that raised about $161.3 million. It also announced FDA clearance for its upcoming Mint patch‑pump, targeting a U.S. commercial launch in the first quarter of 2027.
Why it matters
The higher revenue guidance suggests stronger demand and may improve future cash flow (the company says it expects the guidance raise). FDA clearance enables the Mint product to enter the market, potentially expanding the company’s addressable base.
Key facts
- 1Net sales were $35.5 million, up 30% compared with $27.3 million in the third quarter of 2025. stocktitan.net
- 2Net loss was $24.4 million, or negative 69% of sales, compared with $14.2 million in the prior-year quarter. stocktitan.net
- 3Gross margin was 57.3%, up 179 basis points from 55.5% a year earlier. stocktitan.net
- 4Full‑year 2026 revenue guidance was raised to approximately $124 million to $126 million (previously $121 million to $126 million). stocktitan.net
- 5The company completed a public offering of common stock, raising approximately $161.3 million in net proceeds. stocktitan.net
- 6Beta Bionics announced FDA clearance of its Mint patch‑pump and expects a U.S. commercial launch in Q1 2027. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.